Arch Chemicals

United States

Arch Chemicals, Inc. was a United States-based specialty chemicals manufacturer with a focus on water treatment and microbial control products. The company developed biocides and other performance chemicals for industrial applications including pulp and paper processing, oilfield operations, and recreational water systems. Its product range included both traditional and advanced formulations aimed at improving efficiency and safety in chemical processes.

Read more

Headquartered in Norwalk, Connecticut, Arch Chemicals operated manufacturing sites and distribution networks across North America, Europe, and other regions. It served customers in multiple sectors with solutions for disinfection, preservation, and water purification. The firm emphasized research and development to meet evolving regulatory standards and customer needs in the chemical industry.

In 2011, the company was acquired by Lonza Group AG, a Swiss multinational, in a transaction valued at around 1.4 billion US dollars. This acquisition integrated Arch's portfolio into Lonza's specialty ingredients business, strengthening its position in the global microbial control market. The move allowed for expanded capabilities in product development and global reach.

Prior to the acquisition, Arch Chemicals was a publicly listed entity known for its innovation in sustainable chemical technologies. It played a significant role in the specialty chemicals industry by providing effective and environmentally conscious products to address challenges in water management and hygiene. The company's contributions helped advance practices in industrial water treatment and personal care applications worldwide.

Projects Arch Chemicals is involved in

None yet. When a new project in the record names Arch Chemicals as owner, partner or investor, it shows here.

Active projects close to Arch Chemicals

Arch Chemicals in chemical industry news

2 November 2026
Celanese Q3 2026 earnings beat and raises full-year outlook

Q3 adjusted EPS $1.65 on $2.6B sales (+6% y/y); Q3 free cash flow $461M; raised full‑year adjusted EPS to $6.00–6.25 and FCF outlook to $750–800M.